TPIV Looks To Bounce Back Following Strong Fundamental Developments

Sign Up For Our FREE E-mail Newsletter-> HERE <-To Receive Our Penny Stock Expert Picks Now!

Visit our Twitter page for real-time updates, click here: Penny Stock Experts

Hi Everyone & Welcome New Subscribers,

We hope all of you are enjoying a beautiful weekend. Here, like almost everywhere else, it’s unusually warm for this time of the year, but hot is better than cold. Our main focus over the past few weeks, TPIV (TapImmune, Inc.), started the week off hot, reaching new highs of .97, but ended the week pretty cold after closing at .70.

Shares of TPIV are still up considerably from our initial heads up, and after the fundamental improvements announced by the company last week we expect shares to bounce back from here above .80 or more again soon.

The stock has had heavy support near it’s 50 day moving average since our coverage began, and we will look for that to be a point of major support should the .64 level (where it currently sits) comes into play.

Last week the company announced that they had received Orphan Drug Approval from the FDA for one of their vaccines, TPIV 200, in the treatment of ovarian cancer.

Read the full press release, HERE, for yourself.

We expect TPIV might have even more to share with investors over the coming weeks, which is even more reason why we think shares will bounce back over the short term.

If TPIV can go as far to break above it’s most recent high of .97, and breach the $1.00 level shortly after, we might see a true double from our multiple alerts near .60 over the past month, which would make for a very fine way to end the year.

Keep TPIV on top of your watch list for Monday!

Happy Trading!

Sign up-> NOW <-To Join Our E-mail List!


The Penny Stock Experts Team At

Please read our legal Disclaimer below:

We continue trade up to 100,000 shares of TPIV which we have purchased on the open market with our own money. We have no communication with the company nor any affiliates. We may add to this position or sell it entirely at any time. We have no position at this time.

This disclaimer is to be read in its entirety, and fully understood before using or joining the email list. reserves the right to revise, amend, or modify our Privacy Policy, our Disclaimer, and our other policies and agreements at any time and in any manner by updating their postings. You are responsible for regularly reviewing these terms, conditions, and notices, and any additional terms posted on Your continued use of the website and/or email newsletter after the effective date of such changes constitutes your acceptance of and agreement to such changes. If we should update this disclaimer, we will post the updates to this page on DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS WEBSITE OR IN ONE OF OUR NEWSLETTERS.

Neither nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered st ock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.

We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.

Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website.

Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that and it’s affiliates can buy or sell more shares at any time. We can add or decrease this position at anytime following this e-mail or post. and/or it’s affiliates may receive compensation for e-mail alerts.

To view our full compensation disclosure please visit does not accept free-trading shares as a form of payment.